High promoter hypermethylation frequency of p14/ARF in supratentorial PNET but not in medulloblastoma

被引:23
作者
Inda, MM
Muñoz, J
Coullin, P
Fauvet, D
Danglot, G
Tuñón, T
Bernheim, A
Castresana, JS
机构
[1] Univ Navarra, Lab Neurooncol Mol, E-31008 Pamplona, Spain
[2] Inst Gustave Roussy, UMR 1599 CNRS, Lab Genom Cellulaire Canc, Villejuif, France
[3] Hosp Navarra, Serv Anat Patol Neuropatol, Pamplona, Spain
关键词
CDKN2A; p14ARF; p16; PNET; promoter methylation;
D O I
10.1111/j.1365-2559.2006.02374.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: Medulloblastoma (MB) is the most common primitive neuroectodermal tumour (PNET) of the central nervous system. Although supratentorial PNET (sPNET) and MB are histologically similar, their clinical behaviour differs, sPNET being more aggressive than MB. The aim of this study was to determine whether sPNET and MB are genetically different entities. Methods and results: We investigated 32 PNET primary tumour samples (23 MB and nine sPNET) and four PNET cell lines, for the presence of CDKN2A homozygous deletions at exon 1-alpha of p16/INK4 and exon 1-beta of p14/ARF, and promoter hypermethylation of both genes. No homozygous deletion of either p16/INK4 or p14/ARF was demonstrated in any of the PNET primary tumour samples. Methylation of p16/INK4 was found in one of six sPNET and in one of 23 MB, while p14/ARF methylation was observed in three of six sPNET and in three of 21MB. No methylation of p16/INK4 or p14/ARF was found in any of the PNET cell lines analysed. The three MB cell lines did not show p16/INK4 expression, and only the MB Daoy cell line (homozygously deleted at CDKN2A) presented loss of p14/ARF expression. Conclusions: Our results in this limited series of central PNET show that p14/ARF is frequently involved in PNET carcinogenesis, with a higher frequency, but not statistically significant, for sPNET than for MB.
引用
收藏
页码:579 / 587
页数:9
相关论文
共 36 条
  • [1] ADESINA AM, 1994, CANCER RES, V54, P5649
  • [2] [Anonymous], 2000, World Health Organisation Classification of Tumours: Pathology and genetics of tumours of the nervous system
  • [3] N-MYC AND C-MYC ONCOGENES AMPLIFICATION IN MEDULLOBLASTOMAS - EVIDENCE OF PARTICULARLY AGGRESSIVE-BEHAVIOR OF A TUMOR WITH C-MYC AMPLIFICATION
    BADIALI, M
    PESSION, A
    BASSO, G
    ANDREINI, L
    RIGOBELLO, L
    GALASSI, E
    GIANGASPERO, F
    [J]. TUMORI, 1991, 77 (02) : 118 - 121
  • [4] P16 deletion and mutation analysis in human brain tumors
    Barker, FG
    Chen, PC
    Furman, F
    Aldape, KD
    Edwards, MSB
    Israel, MA
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1997, 31 (1-2) : 17 - 23
  • [5] BATRA SK, 1994, LAB INVEST, V71, P621
  • [6] Biegel J A, 1999, Neuro Oncol, V1, P139, DOI 10.1093/neuonc/1.2.139
  • [7] ISOCHROMOSOME-17Q IN PRIMITIVE NEUROECTODERMAL TUMORS OF THE CENTRAL-NERVOUS-SYSTEM
    BIEGEL, JA
    RORKE, LB
    PACKER, RJ
    SUTTON, LN
    SCHUT, L
    BONNER, K
    EMANUEL, BS
    [J]. GENES CHROMOSOMES & CANCER, 1989, 1 (02) : 139 - 147
  • [8] BIGNER SH, 1990, CANCER RES, V50, P8017
  • [9] STRUCTURAL CHROMOSOMAL-ABNORMALITIES IN HUMAN MEDULLOBLASTOMA
    BIGNER, SH
    MARK, J
    FRIEDMAN, HS
    BIEGEL, JA
    BIGNER, DD
    [J]. CANCER GENETICS AND CYTOGENETICS, 1988, 30 (01) : 91 - 101
  • [10] Chromosome arm 17p deletion analysis reveals molecular genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumors of the central nervous system
    Burnett, ME
    White, EC
    Sih, S
    vonHaken, MS
    Cogen, PH
    [J]. CANCER GENETICS AND CYTOGENETICS, 1997, 97 (01) : 25 - 31